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DEVELOPMENT AND EARLY VALIDATION OF A PATIENT REPORTED OUTCOME 
MEASURE TO ASSESS SLEEP AMONGST PEOPLE EXPERIENCING PROBLEMS WITH 
ALCOHOL OR OTHER DRUGS 
ABSTRACT 
Study Objectives: To develop a patient reported outcome measure to assess sleep amongst people 
experiencing problems with alcohol or other drugs. 
Methods: Item development included secondary analyses of qualitative interviews with drug/alcohol 
users in residential treatment, a review of validated sleep measures, focus groups with drug/alcohol 
users in residential treatment, and feedback from drug/alcohol users recruited from community and 
residential settings. An initial version of the measure was completed by 549 current and former 
drug/alcohol users (442 in person [IP] and 107 online [OL]). Analyses comprised classical test theory 
methods, exploratory and confirmatory factor analysis, measurement invariance assessment, and item 
response theory (IRT). 
Results: The initial measure (30 items) had good content and face validity, and was named the 
Substance Use Sleep Scale (SUSS) by addiction service users. After 7 items were removed due to low 
item-factor loadings, 2 factors were retained and labelled: ‘Mind and Body Sleep Problems’ (14 
items) and ‘Substance Related Sleep Problems’ (9 items). Measurement invariance was confirmed 
with respect to gender, age, and administration format. IRT (information) and classical test theory 
(internal consistency, stability) indicated measure reliability. Standard parametric and non-parametric 
techniques supported convergent and discriminant validity. 
Conclusions: SUSS is an easy-to-complete patient reported outcome measure of sleep for people with 
drug/alcohol problems. It can be used by those concerned about their own sleep, and by treatment 
providers and researchers seeking to better understand, assess, and potentially treat sleep difficulties 
amongst this population. Further validity testing with larger and more diverse samples is now 
required. 
 
KEYWORDS: Sleep, measurement, PROM, drugs, alcohol, addiction treatment   
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STATEMENT OF SIGNIFICANCE 
 
The Substance Use Sleep Scale (SUSS) is the first sleep measure designed specifically for people 
experiencing problems with alcohol or other drugs. It comprises 23 items and 2 factors: ‘Mind and 
Body Sleep Problems’ and ‘Substance Related Sleep Problems’. SUSS was developed with significant 
input from substance users and can be used by them to monitor and reflect on their own sleep; by 
treatment providers to encourage and enable people who use substances to think about sleep and 
identify strategies for improving sleep; and by researchers and others as an outcome measure when 
designing and implementing sleep interventions for this population. Further validity testing, involving 
larger and more diverse samples, is now needed. 
 
 
INTRODUCTION 
 
In a comprehensive review of the biomedical literature on sleep and substance use disorders, Arnedt 
et al. report that ‘nearly all substances ingested prior to bedtime alter the subjective and objective 
experience of sleep’ (p.527).1 For example, the acute administration of drugs in the opioid class can 
increase nocturnal arousals and stage shifts, decrease total sleep time and sleep efficiency, and reduce 
the time spent in Rapid Eye Movement (REM) sleep. Alcohol suppresses REM sleep in healthy 
individuals and is associated with short sleep duration in people who are alcohol dependent. 
Additionally, people experiencing sleeping difficulties often consume drugs or alcohol to help them 
fall asleep - thus indicating that sleep problems are a risk factor for substance misuse.1 
 
The sociological literature on sleep and substance use disorders is less well developed than the 
biomedical literature, although complex interactions between sleep, substance use, treatment and 
recovery processes have been reported. In one qualitative study of current and former heroin users, 
participants repeatedly complained that sleeping problems caused them to feel distressed, exhausted 
and unable to cope.2,3 Sleep tended to worsen during periods of detoxing, with individuals reporting 
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difficulty falling asleep, waking throughout the night, waking early in the morning, having ‘restless’, 
‘jumpy’ and ‘twitchy’ legs, and vivid dreaming (including nightmares and disturbing dreams with 
drug-using content). Difficulties sleeping and tiredness constrained their capacity to participate in 
therapeutic activities when in treatment, had the potential to trigger relapse, and generally undermined 
recovery efforts.2,3  
 
In another qualitative study (comprising focus groups with people reporting a drink or drug problem, 
being treated in residential detoxification or rehabilitation, or defining themselves as abstinent), 
‘sleeping well’ was consistently identified as an important indicator of recovery from addiction.4 This 
finding supported the earlier study of current and former heroin users in which individuals who were 
attempting to reduce or abstain from heroin use described how they tried hard to establish more 
regular sleeping patterns, explained that they often found the structured bedtime routines of residential 
drug treatment helpful, and expressed relief and satisfaction when sleep patterns started to improve.3  
 
Within the general population, the relationship between sleep and health (physical and mental) has 
been widely documented.5,6 Sleep deficiency is associated with anxiety and depression, weight gain, 
impaired immune response, and increased risk of numerous diseases.5-11 Tiredness decreases motor 
and cognitive performance, reducing communication and decision-making, impairing memory and 
concentration, and increasing the risk of accidents and injuries.5,6,12,13 Sleep duration has also been 
linked to all-cause mortality in a number of populations.5,6,14,15 Given the importance of sleep to 
health, scientists and clinicians have developed ways of evaluating sleep and sleep-related 
impairments.5 These include functional imaging and electrophysiologic techniques and actigraphy. 
However, the most practical and widely used tools for evaluating sleep are self-report instruments; for 
example sleep diaries, but also questionnaires that have been validated to assess particular types of 
sleep disturbance or to characterize symptoms of particular sleep disorders.5  
 
Although validated sleep measures have been used in a number of studies of people addicted to 
alcohol or other drugs,16-22 there is currently no sleep measure developed explicitly for people 
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experiencing substance dependence. This is a limitation given that individuals who report problems 
with alcohol or other drugs may experience particular constellations of sleep-related difficulties, 
which change depending on the substances taken, whether an individual is detoxing or not, and 
whether an individual has sleep routines imposed on them (e.g. in residential treatment or prison). The 
lack of a specific standardized validated questionnaire makes it difficult for those experiencing 
substance-related impaired sleep to convey the nature and strength of their sleep problems. It also 
poses challenges for those seeking to better understand, assess, and potentially treat sleep difficulties 
amongst alcohol and other drug users.  
 
Self-completion questionnaires that assess subjective health status are often referred to as Patient 
Reported Outcome Measures (or PROMs).23 PROMs are used across many areas of medicine, but 
have received comparatively less attention from within the drug and alcohol sector; perhaps reflecting 
the fact that historically alcohol and other drug users have not tended to be widely consulted by 
treatment providers or scale developers. Although the methodology for developing PROMs is 
constantly evolving, it is generally agreed that individuals from the target patient population should be 
involved in item and scale development. This helps to ensure that the constructs measured and the 
language and terminology used are acceptable to, and reflect the priorities and preferences of, those 
who will later complete the measure.4,24,25 Once developed, PROMs should be subjected to rigorous 
psychometric testing.23  
 
The aim of our study was to develop a new PROM to assess sleep amongst people experiencing 
problems with alcohol or other drugs. The work was undertaken in two phases. Phase 1 identified 
items for the new PROM (ensuring good face and content validity, acceptability and usability for the 
target population). Phase 2 then evaluated the psychometric properties and factorial structure of the 
new PROM. The study received ethical approval from a University Research Ethics Committee. 
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METHODS 
	  
Phase 1 (hereafter, ‘item development’) occurred in 3 stages between July and October 2015. Data 
collection for Phase 2 (hereafter, ‘measurement evaluation’) occurred in 2 subsequent stages between 
November 2015 and August 2016. To be eligible to participate in the study, individuals needed to: i. 
be over 18 years of age, ii. self-report current or previous problem substance use (illicit drugs or 
alcohol), iii. have sufficient understanding of English to be able to complete a basic questionnaire 
alone or with reading support, and iv. be able to give informed consent. 
 
Support and advice were provided to the research team by two separate Project Advisory Groups 
(PAGs). The first PAG (PAG 1) comprised addiction service users, addiction clinicians and 
researchers, sleep clinicians and researchers, and a PROM expert (n=10); it met once during 
November 2015. The second PAG (PAG 2) comprised addiction service users only (n=11); this group 
met several times throughout the study and also provided ad hoc advice on a small group and 
individual basis by telephone, email, and in person as issues needing discussion arose. Service user 
advisors were each paid £20 per consultation; other advisors were not paid. 
 
Item development 
 
Stage 1: Identifying candidate items 
 
Stage 1 involved secondary analyses of a pre-existing qualitative data set generated during a separate 
but linked study of sleep and addiction in residential rehabilitation settings.26,27 This prior study had 
been undertaken in residential treatment services in England during 2014 and 2015. Semi-structured 
interviews had been conducted with 19 women and 9 men (n=28). Their ages had ranged from 24-83 
years, and they had self-reported a mixture of alcohol, illicit drug, and prescription drug misuse. For 
the present study, the transcribed interview data were re-analysed to identify sleep-related themes that 
might constitute candidate items for the new PROM.  
	   7 
 
In addition, the research team separately reviewed twelve validated sleep measures that had all 
previously been used in studies of people addicted to drugs or alcohol (see Supplementary table S1). 
Items that complemented or supported the themes discussed in the 28 qualitative interviews were 
added to the list of candidate PROM items. The list was then screened by four addiction service users 
(2 men and 2 women) from PAG 2. The four PAG 2 members were asked to suggest additional items, 
reword items, or remove irrelevant items. They were also consulted on the most appropriate time scale 
and scoring system for the new PROM. 
  
Stage 2: Creating a draft measure 
 
In Stage 2, all the candidate items identified in Stage 1 were discussed within 2 focus groups of 
treatment clients. Focus group participants were recruited from two residential services, both of which 
provided detoxification and structured support (neither service had been involved in Stage 1). 
Participants included 9 men and 3 women (n=12), their ages ranged from 27-47 years, and they 
reported misuse of alcohol, illicit drugs, and prescribed drugs (often in combination). Each focus 
group participant received a £15 shopping voucher in compensation for their time.   
 
The focus group participants were invited to debate the long list of candidate items from Stage 1, add 
new items, suggest any changes to wording, or remove any items. Feedback from the focus groups 
was discussed with members of PAG 2 on two separate occasions and the long list of items was 
revised according to their advice. Following this, a draft sleep PROM was prepared by the research 
team. 
 
Stage 3: Assessment of face and content validity, acceptability and usability 
 
In Stage 3, a new sample of 30 current and former drug and alcohol users completed the draft PROM 
in person, commenting on the content, time scale, wording, scoring system, and layout. Participants 
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were recruited through a variety of community settings (n=22), residential settings (n=4), and an 
outreach setting for people sleeping on the streets (n=4). They included 26 men and 4 women; age 
range = 29-65 years. In total, 27 had used drugs or alcohol in the last six months. Of these, 10 
reported that their main substance was an illicit drug, 8 reported that their main substance was 
alcohol, and 9 reported that they used illicit drugs and alcohol equally. All participants received a £15 
voucher in compensation for their time. The research team used the participants’ feedback to modify 
the draft sleep measure and the modified version was then discussed with PAG 1 members. 
 
Measurement evaluation 
 
Stage 4: In person (IP) sample  
 
For stage 4, we recruited current and recent drug and alcohol users (n=442) from community 
treatment services, homeless hostels, and peer support services across five English towns and cities. 
These individuals completed a questionnaire that comprised basic demographic, drug use and sleep 
questions and the draft sleep measure. To maximise recruitment and completion, the questionnaire 
was kept as short as possible so that it could be answered relatively quickly (< 15 minutes), even by 
people who might have limited literacy or find it difficult to concentrate due to drug or alcohol 
withdrawal symptoms. Participants were offered refreshments to compensate for their time. 
 
In order to conduct more advanced validation work, additional data (including some follow-up data) 
were required. As we were concerned about the burden this would place on our target population, and 
also the difficulty of tracking and relocating participants across many locations simultaneously, we 
only collected these additional data from a sub-sample of participants attending services in one city. 
We recruited to pre-set targets that we believed would be both feasible and adequate for the analyses 
and front-ended the data collection to ensure that our targets were met. Accordingly, the first 100 
participants also completed two validated measures: i. the Pittsburgh Sleep Quality Index (PSQI)28 
and ii. the Substance Use Recovery Evaluator (SURE).29 The PSQI is a self-rated questionnaire which 
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assesses sleep quality and disturbances over a one-month time interval; score range 0-21 where lower 
scores denote better sleep quality. SURE is a psychometrically valid PROM for recovery from drug 
and alcohol dependence; score range 21-63 where higher scores denote greater recovery. Of these 100 
individuals, the first 42 completed the questionnaire and validated measures a second time, 2-5 days 
later. These 42 individuals received a £10 supermarket voucher for each questionnaire completed. Of 
these 42 individuals, 22 also wore actigraphs for a period of 7 days. These 22 participants received a 
further £10 voucher for the inconvenience of wearing the watches. 
 
Stage 5: Online (OL) sample 
 
To expand the geographical reach of the data collection and to ensure that we recruited beyond 
current treatment populations, an online version of the demographic, drug use and sleep questions and 
the sleep measure was created using the survey tool BOS (https://www.onlinesurveys.ac.uk/). The 
online survey was open to anyone who was currently in, or who had previously been in, community or 
residential treatment for an alcohol or other drug problem. The survey link was circulated to service 
user organisations and treatment services via social media (Twitter, LinkedIn) and email. No 
compensation was offered for completing the survey. In total, 107 individuals responded online. 
 
Statistical analysis 
 
Actigraph data were entered into the software programme Sleep Analysis 7 and estimates of i. sleep 
efficiency, ii. sleep latency, iii. total sleep time, and iv. wake bouts for each participant were created. 
We used parametric (t-test, Pearson’s correlation coefficient) and non-parametric methods (Mann-
Whitney test, Spearman’s correlation coefficient) to test score differences and associations, subject to 
the symmetry of the distributions.  
 
To assess the reliability of the new measure, both classical test theory (internal consistency and 
stability) and item response theory (IRT; information) approaches were used. Internal consistency was 
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evaluated via Cronbach’s alpha coefficient,30 along with the item-total correlations and the 
computation of the alpha if the item was omitted. Stability was evaluated via Cohen’s Kappa for each 
item,31 following Landis and Koch interpretations,32 along with the percentage of agreement. For the 
total scores (continuous variables), a (two-way mixed) intra-class correlation coefficient33 was also 
calculated.  
 
We performed item factor analysis (IFA)34 suitable for binary items to identify the dimensionality of 
the measure. Both exploratory (EFA) and confirmatory (CFA) models were used, in different 
samples. Measurement bias (or violation of measurement invariance) was evaluated via multiple 
groups CFA for categorical exogenous variables (group membership)35-37. This was conducted in three 
stages. First, metric invariance was tested by restricting the loading of each item to its corresponding 
factor to be equal across groups. Each item that demonstrated metric invariance was equivalently 
related to its factor across groups. Second, scalar invariance was tested by restricting the thresholds of 
each item so that they were equal across groups. Each item that showed scalar invariance had the 
same probability of a positive response for individuals of the same trait levels across groups. Third, 
strict invariance was tested by restricting the residual variances of each item so that they were equal 
across groups. Each item that demonstrated strict invariance was explained similarly by their factor 
across groups. For continuous exogenous variables, such as age, measurement invariance was tested 
using the Multiple Indicators, Multiple Causes model (MIMIC).38,39 A significant direct effect from 
the exogenous variable to a particular item demonstrated a lack of metric invariance, so raising 
concerns of measurement bias.  
 
Whereas classical test theory assesses the whole test or the unit of measurement, Item Response 
Theory (or IRT) examines individual items or questions. IRT is a probabilistic model of the 
mathematical relationship between individuals’ abilities (or other hypothesized traits) and the item 
characteristics. In other words, the probability that an individual will respond positively or correctly to 
an item designed to measure a particular trait is a function of the item’s difficulty, the item’s 
discrimination ability, and the amount of the underlying trait possessed by the individual. The 2-
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parameter IRT model (2PL-IRT)40 was used to evaluate the severity (difficulty), discrimination 
ability, and information (precision) of the items within each dimension of the final measure. Evidence 
of (concurrent) convergent and divergent validity was assessed via standard parametric and non-
parametric techniques, as described above. The statistical software Mplus (version 7) was used for all 
latent trait models (IRT, IFA, EFA, CFA and MIMIC). 
 
 
RESULTS 
 
Item development outcome 
 
Stage 1: Identifying candidate items 
 
Secondary analyses of the 28 qualitative interviews identified 72 themes for consideration as 
candidate PROM items (see Supplementary table S2). Following review of the 12 validated sleep 
measures, 21 new themes were added to the list of candidate items for the new sleep PROM (see 
Supplementary table S3). In consultation with the four PAG 2 members, the long list of candidate 
items was turned into 75 simple ‘no’/ ‘yes’ statements relating to sleep in the previous week (see 
Supplementary table S4). Binary response options were preferred over polytomous response options 
because they were considered easier for respondents to understand and complete. The last week was 
preferred over shorter and longer time frames as this was deemed long enough to capture sleep 
patterns without responses being undermined by poor recall. Supporting this, there is good evidence 
that other sleep-related PROMs, such as the Pittsburgh Sleep Quality Index and the Epworth Sleep 
Scale, can be administered with confidence for week-long reporting periods for between-subject 
analyses.41 The expression ‘last week’ was preferred to ‘last 7 days’ since the word ‘days’ could 
generate confusion amongst a population that has a tendency to sleep during the daytime (rather than 
at night) when using substances but not when in treatment or abstinent.2,3 
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Stage 2: Creating a draft measure 
 
Feedback from the focus group participants and PAG 2 members indicated that some of the 75 sleep 
statements needed to be amended or removed. A key problem was that many focused on sleep 
‘behaviors’ rather than sleep ‘problems’, and these indicators of sleep behavior were not necessarily 
indicative of sleep problems. For example, discussions revealed that ‘sleeping with the television or 
radio or music on’ or ‘drinking a hot drink before bed’, or ‘napping during the day’ could help some 
people to sleep, impede the sleep of others, and have no effect on yet others. Items considered 
ambiguous by the PAG were therefore removed.  
 
The resultant draft PROM comprised 30 x ‘no’/ ‘yes’ statements (scoring ‘0’ and ‘1’; a higher score 
denoting more sleep problems). These statements focused on the previous week and related to seven 
broad aspects of sleep: ‘sleep satisfaction’, ‘sleep environment’, ‘falling asleep’, ‘night time activity’, 
‘sleep quality’, ‘waking up’, and ‘daytime functioning’ (see Supplementary table S5). 
 
Stage 3: Assessment of face and content validity, acceptability and usability 
 
In the final development stage, 30 individuals completed the draft PROM. In response to a series of 
structured questions, all 30 reported that the PROM was easy to understand, all 30 reported that it was 
easy to complete, 27 reported that the length was about right (two said it was too short and one said it 
was too long), and 20 reported that they had enjoyed completing it (10 felt neutral and nobody 
actively disliked it). In total 28/30 said there were no irrelevant questions and 28/30 thought the 
PROM covered everything necessary. Completion times ranged from 2–20 minutes (mean 9 minutes; 
with those taking longer often discussing their responses with the researcher because they seemed to 
be finding the questionnaire interesting). Following consultations with members of PAG 1, only a 
small number of minor wording changes were made, and good face and content validity, acceptability 
and usability were confirmed. Members of PAG 2 named the measure the Substance Use Sleep Scale 
(SUSS). 
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Measurement evaluation outcome 
 
Sample characteristics 
 
Several differences between the demographic characteristics of the individuals who completed the 
measure in person (IP) and those who completed online (OL) were evident (Table 1). The OL sample 
had higher percentages of women (63.6% vs 30.5%), individuals of white ethnicity (95.3% vs 78.7%), 
and individuals who left school after the age of 16 (77.6% vs 31.4%). Age did not differ significantly 
between the two samples, with the total sample being between 20 and 71 years old. There were no 
differences with respect to length of problem substance use; 9% of the total sample reported less than 
10 years of drug or alcohol problems.  
 
For the exploratory and confirmatory factor analysis, we used a random number algorithm 
(automatically generated by the software SPSS) to divide the IP sample (n=442) into two split halves 
(hereafter, IP-a and IP-b). Randomization produced two split halves that did not differ in terms of 
demographic or clinical characteristics. As the OL sample (n=107) was too small to be similarly 
divided, it was instead used as a second confirmation sample to strengthen the analyses.   
 
 
INSERT TABLE 1 
 
Item selection   
 
We began our analyses by testing for potential problematic items, using classical test theory tools. 
Grouping all items together, Cronbach’s alpha coefficient was 0.88 for the complete sample (IP: 0.88; 
OL: 0.85). In the IP sample, there was no improvement in the reliability index by omitting items, and 
the item–total correlations (bi-serial correlation coefficient r) varied between r=0.3 and r=0.6. In the 
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OL sample, there were some low item–total correlations (varying between 0.1 and 0.6), but no 
substantial reduction in alpha when items were omitted (Table 2). According to Landis and Koch,32 
the level of agreement was fair to perfect (Cohen’s Kappa varied between 0.4 and 1). Agreement was 
higher than 73% in all cases, even for lower values of κ. Therefore, in terms of reliability (according 
to classical test theory assumptions), no problematic items were found and so all items were used in 
the EFA.  
 
INSERT TABLE 2 
 
Exploratory item factor analysis 
 
All 30 items were included in an EFA model (sample IP-a). The sample correlation matrix produced 
seven eigenvalues larger than 1 (12.8, 3.1, 1.8, 1.6, 1.4, 1.1, 1.1). According to Kaiser’s criterion, this 
suggested up to seven extracted factors. The scree plot, however, indicated a two factor solution 
(Figure 1).  
 
INSERT FIGURE 1 
 
Table 3 presents the goodness of fit indices for all models, from the uni-dimensional solution to the 
seven-factor solution. Close fit was achieved at the two-factor solution. Increasing the number of 
factors to three or more resulted in non-salient loadings, cross-loadings and/or factors with a small 
number of items (and thus small reliability). All seven solutions were evaluated in terms of the 
content of the extracted dimensions and the two-factor solution was considered the most satisfactory 
in terms of face validity.  
 
INSERT TABLE 3 
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Three items (‘disturbed by noise’, ‘disturbed by light’, and ‘woken up in the night and drunk 
caffeinated and/ or sugary drinks’) had loadings equal to or less than 0.3 on both factors, so they were 
omitted and the analysis was repeated. Four more items (‘sleeping tablets or medicines to help me 
sleep’, ‘woken up short of breath’, ‘needed caffeine and/ or sugary foods or drink to get through the 
day’, ‘needed to sleep or to nap during the day’) were then also omitted since they had smaller 
loadings compared to the rest of the items within their factor (<0.6 in all cases). This was undertaken 
as a stepwise procedure, omitting one item at the time (but only where omitting the item increased the 
content validity of the corresponding factors, as judged by the research team). The 2-factor model was 
then re-fitted for the remaining items. The process stopped when a) all items loaded at least 0.6, b) the 
goodness of fit measures indicated a robust solution, and c) team members confirmed that the content 
of each factor was adequately described by the items. The final solution had close fit to the data: rel 
χ2=1.66, RMSEA=0.055 with 95% CI: (0.04, 0.07), CFI=0.95, TLI=0.94. The corresponding EFA 
loadings, under OBLIMIN rotation, are presented in Table 4. 
 
INSERT TABLE 4 
 
Confirmatory item factor analysis  
 
The 2-factor (23-item) solution also had a close fit to the IP-b data: rel χ2=1.82, RMSEA=0.061 with 
95% CI: (0.05, 0.07), CFI=0.94, TLI=0.94. Additionally, the values of the goodness of fit indices and 
the loadings resembled those in EFA (Table 4). CFA was next applied to the OL sample data, 
revealing a close fit (rel χ2=1.31, RMSEA=0.054 with 95% CI: (0.03, 0.07), CFI=0.92, TLI=0.92) and 
large loadings.  
 
The two factors were named based on the content of their items, with factor 1 referred to hereafter as 
‘Mind and Body Sleep Problems’ (MBSP) and the second factor referred to as ‘Substance Related 
Sleep Problems’ (SRSP). 
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Measurement invariance 
 
The next stage of our analysis involved testing for potential measurement bias in relation to how the 
data were collected (IP or OL), age, and gender. For this, the two random split halves were combined 
and the total IP sample was used.  
 
Invariance in IP and OL samples 
 
Metric invariance held between the OL and IP samples (DIFFTEST: χ2=30.51, df=20, p=0.06). Full 
scalar invariance did not hold (DIFFTEST: χ2=54.83, df=20, p<0.001) and the modification indices 
suggested that the fit of the model could be improved by allowing the thresholds of the items ‘drunk 
alcohol to help me sleep’ and ‘woken up with a hangover or drunk’ to vary. By allowing this, partial 
scalar invariance was held (DIFFTEST: χ2=22.42, df=18, p=0.214). When evaluating the residual 
variances, strict invariance also held (DIFFTEST: χ2=30.68, df=22, p=0.103).   
 
All items related to their factor (MBSP or SRSP) similarly across the IP and OL samples (metric 
invariance). For 21/23 items, individuals who completed the questionnaire IP had the same expected 
response as individuals who completed the questionnaire OL, when they had the same levels of 
MBSP and SRSP (partial scalar invariance). However, for the same levels of SRSP, the IP sample had 
a greater probability of reporting ‘drinking alcohol to help sleep’ (threshold: IP=0.68, OL=-0.45) and 
a greater probability of reporting ‘waking up with a hangover’ (threshold: IP=1.1, OL=-0.32). The 
amount of item variance explained by each factor was the same across the IP and OL samples for all 
items (strict invariance).  
 
As there was full invariance with respect to loadings and residuals and 91% invariance with respect to 
the thresholds, we concluded that there was no substantial measurement bias and the IP and OL 
samples were merged for the remaining analyses. 
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Invariance with respect to gender and age 
 
When the IP and OL data were combined for the gender and age invariance tests, full measurement 
invariance held with respect to gender (Metric DIFFTEST: χ2=19.72, df=21, p=0.539; Scalar 
DIFFTEST: χ2=29.75, df=21, p=0.097, Strict DIFFTEST: χ2=21.74, df=23, p=0.536). 
 
We then used the MIMIC model to detect direct effects of age (measured on a continuous scale) on 
individual items. Assuming the same levels of MBSP, increasing age was associated with reduced 
probability of people reporting both ‘difficulty falling asleep’ (d.e.=-0.025, p=0.001) and ‘negative 
emotions when trying to sleep’ (d.e.=-0.023, p=0.004). In contrast, for the same levels of MBSP, 
increasing age was associated with increased probability of people reporting ‘aches and pains that 
stopped sleeping’ (d.e.=0.044, p<0.001). For the same levels of SRSP, the probability of reporting 
‘drinking alcohol to help sleep’ (d.e.=0.024, p=0.018) and ‘waking up in the night and drinking 
alcohol’ (d.e.=0.044, p<0.001) both increased with age. However, the magnitude of the direct effects 
was very small and our results therefore indicated that age did not bias measurement. 
 
Item response theory  
 
IRT was performed separately on each factor to evaluate the severity (difficulty), discrimination 
ability, and information (precision) of each item separately. Given the lack of substantial 
measurement invariance, we used the complete sample for these analyses (n=548). Figure 2 depicts 
the item characteristic curves (ICC, for the severity and discrimination ability of the items) and the 
information curves (IFC, for the level of precision provided by the items) for each item within its 
factor. The severity and discrimination parameters are presented in Table 5 and the item and test 
information for each factor is shown in	  Supplementary table S6.  
 
INSERT FIGURE 2 
INSERT TABLE 5 
	   18 
 
Mind and Body Sleep Problems 
 
In terms of mind and body sleep problems (MBSP), ‘wanting to sleep better’ was the least severe item 
and it was more likely to be reported by people with less than average MBSP scores. The most severe 
item was ‘felt too unsafe to sleep’, which was more likely to be reported by individuals with above 
average MBSP scores. The MBSP items best able to discriminate between individuals with different 
severity of mind and body sleep problems were ‘uncontrollable/ racing thoughts when I tried to sleep’ 
and ‘negative emotions when I tried to sleep’. Thus, reporting or not reporting one of these two 
problems made the largest difference in the expected quality of sleep. These two items were also the 
most informative (precise) for individuals with average sleep quality ± 1 Standard Deviation (SD). 
For individuals with higher levels of MBSP, ‘felt too unsafe to sleep’ and ‘experiencing panic attacks 
in the night’ were the most informative items. For individuals with lower levels of MBSP, ‘wanting to 
sleep better’ and ‘woken up tired most mornings’ were the most informative.  
 
The IFCs indicated that the MBSP items could measure problems precisely across the MBSP 
continuum; indeed, both the ICCs and the IFCs were spread across the MBSP latent continuum 
(Figure 2). 
 
Substance Related Sleep Problems 
 
Turning to substance related sleep problems (SRSP), ‘vomited in my sleep’ was the most severe item 
and ‘woken up in the night and smoked tobacco’ was the least severe. ‘Woken up in the night and 
drunk alcohol’, ‘woken up in the night and used street drugs’, and ‘needed alcohol or drugs to get out 
of bed’ were the most discriminative, although most items performed similarly well. For individuals 
with up to average SRSP, ‘needing alcohol or drugs to get out of bed’ was the most informative item. 
For higher levels of SRSP, most IFCs peaked at about 1 SD above average. That is, the precision of 
the items was maximised for individuals with SRSP scores close to 1 SD above average. ‘Vomiting in 
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my sleep’ had low precision for individuals with low to up to 1 SD above average SRSP levels. 
However, for high SRSP levels, ‘vomited in my sleep’ was the most informative item; indicating that 
this question was particularly useful for identifying individuals with severe substance related 
problems.  
 
Whilst the ICCs of MBSP were spread over the latent continuum (± 2 SD from the mean), the 
characteristic curves of the SRSP items were located at above average sleep problems. This indicated 
that SRSP items pertained largely to very poor quality sleep. 
 
Reliability and validity 
 
Reliability 
 
Reliability tests on the final 23-item sleep PROM showed that Cronbach’s alpha coefficient was still 
0.88 for the complete sample, with no improvement in the reliability index gained by omitting items. 
The item–total correlations varied between r=0.3 and r=0.6. For MBSP, alpha was 0.86 (item-item 
correlations: 0.2-0.6; item-total correlations: 0.4-0.6) and no problematic items were found. For 
SRSP, which comprised a smaller number of items, alpha was 0.79 (item-item correlations: 0.14-0.7; 
item-total correlations: 0.3-0.6) and no problematic items were found. Thus, internal consistency was 
granted for the final measure in the complete sample.   
 
With respect to the stability of the final measure, all items had fair to perfect agreement as previously 
reported (Table 2; Cohen’s κ varied between 0.4 and 1).32 With respect to the factor and total scores, 
the intraclass correlation coefficient indicated almost perfect agreement between the two time points 
in all cases (MBSP: 0.96, 95% CI: [0.92, 0.98]; SRSP: 0.97, 95% CI: [0.95, 0.99], TS: 0.96, 95% CI: 
[0.92, 0.98]). We therefore concluded that the measure was reliable, both according to classical test 
theory (internal consistency, stability) and item response theory.  
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Validity 
 
In terms of validity, the new measure correlated moderately to strongly with the PSQI and SURE 
scores demonstrating convergent validity. In contrast, there were only low or non-significant 
correlations with actigraphy scores indicating discriminant validity (see Table 6).  
 
INSERT TABLE 6 
 
The new measure was also able to discriminate between sub-groups of substance users (see Table 7). 
For example, people who reported insomnia had significantly higher factor scores than those who did 
not report insomnia (both factors); people who had been homeless in the last month scored 
significantly higher than those who had not been homeless in the last month (both factors); and people 
who had been in paid work in the last month scored significantly lower than those who had not been 
in paid work in the last month (both factors).   
 
INSERT TABLE 7 
 
Analyses presented in Table 7 also provide further evidence that the two factors are distinct in terms 
of content. Thus, people who reported mental health problems had significantly higher MBSP scores 
than those who did not report mental health problems, but the two groups did not have significantly 
different SRSP scores. Meanwhile, gender and education were not related to MBSP, but were related 
to SRSP.  
 
 
DISCUSSION 
 
Sleep is an important, but frequently overlooked, issue for people addicted to alcohol and other drugs. 
Although there are many validated sleep measures, none has been developed specifically for people 
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experiencing problems with substances and, consequently, there has been no reliable way of assessing 
the self-reported sleep problems of this population. We completed extensive developmental work, 
comprising qualitative and quantitative methods, with significant input from people using drugs and 
alcohol in order to develop our new self-reported outcome measure of sleep problems. Members of 
our service user project advisory group confirmed face and content validity and determined the 
measure’s name: the Substance Use Sleep Scale (SUSS). Statistical analyses established a two-factor 
structure, measurement invariance, reliability and validity.  
 
SUSS is shown in Table 8. It comprises 23 items and 2 factors: factor 1 ‘Mind and Body Sleep 
Problems’ (MBSP) and factor 2 ‘Substance Related Sleep Problems’ (SRSP). Each factor is internally 
coherent. Items score 0 or 1, so total scores range from 0-23 (where lower scores denote better sleep 
and higher scores denote worse sleep). SUSS is worded so that it is accessible to people with limited 
literacy: it has a Flesch readability score (based on number of words per sentence and number of 
syllables per word) of 86.8 and a Lexile Measure (based on word frequency and sentence length) of 
400L-500L. These scores denote easy to read conversational English.  
 
SUSS is quick and easy to complete (as little as 2 minutes). However, individuals frequently took 
longer to complete it because they chose to pause and reflect on individual items and to discuss their 
responses with the researcher. As has been argued previously,25,29 a well-designed PROM will not 
simply generate numeric scores. It will also prompt people to reflect on and volunteer potentially 
important information about their lives and circumstances that might be helpful in a therapeutic 
context. Since only 1/30 people reported that the initial 30-item version of SUSS was too long 
(whereas 2/30 reported it was too short), 20/30 reported that they enjoyed completing it and 28/30 
identified no irrelevant questions (Item development, stage 3), we do not feel that a short-form version 
is an immediate priority for clinical practice. Nonetheless, we recognise that brevity is important 
when scales are used in studies alongside other assessments. IRT is not designed as a method to 
reduce the number of items in a measure, but our IRT parameters fully describe the functionality of 
each item and may thus facilitate item selection in the development of any future short-form. 
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INSERT TABLE 8 
 
Factor 1 (‘Mind and Body Sleep Problems’) comprises 14 items that all relate to cognitive and 
behavioural difficulties and concerns about sleep. These include problems going to sleep 
(‘uncontrollable/ racing thoughts when trying to sleep’, ‘negative emotions when trying to sleep’, 
‘difficulty falling asleep’, ‘feeling too unsafe to sleep’, ‘aches and pains that prevented sleeping’); 
problems staying asleep (‘panic attacks in the night’, ‘waking up lots in the night’, ‘being restless 
during sleep’, ‘dreams that disturbed sleep’); and problems associated with fatigue on wakening and 
during the day (‘waking up tired most mornings’, ‘waking up feeling confused and disoriented’, 
‘being too tired to think clearly or do things during the day’, ‘worrying about sleep’, ‘wanting to sleep 
better’). None of the 14 items explicitly mentions drugs or alcohol and all items could be reported by 
individuals who do not consume substances. Nevertheless, the factor captures aspects of sleep 
(particularly, ‘racing thoughts’, ‘feeling unsafe’, ‘panic attacks’, ‘disturbing dreams’, and ‘waking up 
confused and disoriented’) that are germane to substance users 2,3 and tend not to feature in other more 
generic sleep scales. 
 
Items in Factor 2 (‘Substance Related Sleep Problems’) also relate to difficulties when trying to go to 
sleep, difficulties staying asleep, and difficulties on wakening. However, in contrast to factor 1, all 
factor 2 items (n=9) refer directly or indirectly to substances (drugs, alcohol or tobacco) and none 
would ever be reported by anyone who did not consume substances. Thus, 5 items explicitly mention 
drugs or alcohol (‘waking up in the night and using street drugs’, ‘using street drugs to help sleep’, 
‘waking up in the night and drinking alcohol’, ‘drinking alcohol to help sleep’, ‘needing alcohol or 
drugs to get out of bed’) and one item explicitly mentions tobacco (‘waking up in the night and 
smoking tobacco’). The remaining 3 items (‘woken up with a hangover’, ‘vomited in my sleep’, 
‘woken up withdrawing’) all clearly refer to the consequences of drug or alcohol consumption and 
intoxication. 
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People experiencing problems with drugs and alcohol often report complex physical, psychological 
and social problems that can impede sleep.3,27 Within the general population, bio-psychosocial 
problems also undermine sleep.42 We might therefore expect that people who report problematic 
substance use will experience at least some sleep difficulties independent of their alcohol and other 
drug consumption, such that sleep problems will not simply disappear if they become abstinent. This 
assumption is supported by the 2-factor structure of SUSS which distinguishes more generalized mind 
and body sleep problems from sleep problems related specifically to substance use. Reflecting this, 
we suggest that any interventions or strategies designed to improve the sleep of people who use drugs 
or alcohol will need to address both their substance use and any wider bio-psychosocial problems that 
patient and clients report; addressing substance use alone will likely generate only partial success.43  
 
Invariance testing revealed that participants who reported the same level of mind and body sleep 
problems were less likely to report ‘difficulty falling asleep’ and ‘negative emotions when they tried 
to sleep’ but were more likely to report ‘aches and pains that stopped them from sleeping’ as they 
aged. Meanwhile, participants with the same level of substance related sleep problems were more 
likely to report ‘drinking alcohol to help them sleep’ and ‘waking up in the night to drink alcohol’ as 
they aged. These findings suggest that older people reporting problems with substances may 
experience sleep problems differently from younger people. This may limit the ability of SUSS to 
measure and compare sleep problems across age groups. Nonetheless, the magnitude of the effects 
was low and changes to sleep patterns are part of the normal aging process. Studies have consistently 
shown a decrease in both sleep length and slow-wave sleep and an increase in sleep fragmentation in 
older adults,44,45 as well as adaptation in perceptions of sleep and disturbances as we age.46 Some basic 
differences in perceptions of sleep quality between age groups are therefore to be expected and do not 
notably undermine the utility of SUSS.   
 
The IRT models indicated that items relating to mind and body sleep problems captured high, medium 
and low levels of sleep difficulty, whereas items relating to substance related sleep problems mainly 
captured very poor sleep quality. Thus, people who have low SRSP scores (i.e. people who report that 
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substance use is negatively affecting their sleep) are likely to have especially poor sleep. Addressing 
their substance use may significantly improve (although not necessarily solve) their sleep problems. 
That the only item relating to tobacco ‘woken up and smoked tobacco’ captured sleep quality at the 
higher end of substance related sleep trait suggests that alcohol and other drug use are more closely 
associated with poor sleep than tobacco. Consequently, addressing alcohol and other drugs seems 
more likely to improve sleep than addressing smoking, although reduced use of tobacco should still 
improve sleep quality.47 
 
SUSS, the PSQI and SURE are all self-report measures assessing self-perceived health status, whereas 
actigraphy scores are a more objective measure of sleep based on movement. Given that subjective 
and actigraphic measurement of sleep are known to correlate poorly,48-50 our finding that SUSS 
correlated moderately to strongly with the PSQI and SURE scores but not with the actigraphy scores 
are as anticipated. Similarly, we expected and found that SUSS correlated positively with two 
characteristics likely to be associated with poor sleep (insomnia and homelessness) and negatively 
with one characteristic likely to be associated with good sleep (being in paid work). Meanwhile, 
gender and education were associated with substance related sleep problems but not mind and body 
sleep problems, whereas having a diagnosed mental health problem was related to mind and body 
sleep problems but not substance related sleep problems. These latter findings merit further 
consideration.  
 
Although there is evidence of sex differences in sleep difficulties,51 analysis of large-scale survey data 
has suggested that a major reason why women self-report poorer sleep than men relates to women’s 
disadvantaged socio-economic status.52 Supporting this, Sekine et al. have found that gender 
differences in sleep could be entirely explained by gender differences in work characteristics, 
domestic roles and family work conflicts.53 The lack of association between gender and mind and 
body sleep problems in our analyses may therefore relate to the specific socioeconomic patterns and 
dynamics of alcohol and other drug users. For example, poor education, low income, and 
unemployment tend to be high across both sexes, with some evidence that women may be better than 
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men at managing the finances they do have once substance use stops.3,54 In terms of differences 
between mental health and the two sleep factors, there is a well-known association between poor 
mental health and the general sleep issues comprising factor 1.55,56 There is, however, no current 
evidence of an association between mental health and the items comprising substance related sleep 
problems (factor 2).  
 
Limitations and strengths 
 
Self-report measures of sleep have limitations despite their widespread use.5 Awareness is reduced 
during sleep and this limits the validity of sleep self-reports when assessing objective variables and 
phenomena such as snorting, apnea or leg jerks.5 Sleep can also vary considerably from day to day, 
meaning that multiple measures are often needed to derive stable measures.5 Further validity testing of 
SUSS, based on larger and more diverse samples that would establish factor and total score norms and 
enable other group comparisons, is now needed. This might include people who consume alcohol or 
other drugs but do not consider that they have ever had a problem with substances; people from other 
patient populations who report sleep problems; and people from other countries and cultures where 
language, practices, and expectations relating to both sleep and substance use may vary.  In addition, 
criterion and predictive validity testing would be desirable.  
 
In terms of its strengths, SUSS is the first sleep measure designed specifically for people experiencing 
problems with alcohol and other drugs. Moreover, people who used substances played a central role in 
establishing its content, and confirmed that it had good face validity. The measure was designed using 
a careful and considered blending of qualitative methods (with their focus on subjective meaning and 
understanding) and more objective quantitative techniques. This capitalised on the strengths of each to 
ensure a robust development and early validation process. Our study participants were diverse in 
terms of age, ethnicity, drugs used, and geographical location, so providing reassurances in terms of 
inclusion and diversity. That we successfully collected data online suggests that a computer adaptive 
version can be designed. Lastly, SUSS seems likely to have a number of potentially important 
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functions. It might be used by people who use, or have used, substances to monitor and reflect on their 
own sleep; by treatment providers to encourage and enable people who use substances to think about 
their sleep and its diverse correlates, and to practise, evaluate and deploy strategies for improving 
sleep; and by researchers and others as an outcome measure when designing and implementing sleep 
interventions for this population. 
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Table 1: Descriptive indices by sample and in total  
  In person (N=442) Online (N=107) Total (N=549)  
N % N % N % Comparison 
Age left school  
≤16 years 301 68.1 24 22.4 325 59.2 
χ2 =18.568, df=1, p<0.001 >16 years 139 31.4 83 77.6 222 40.4 
Ethnicity   
White 348 78.7 102 95.3 450 82.0 
χ2 =16.049, df=1, p<0.001 Other 94 21.3 5 4.7 99 18.0 
Gender  
Female 135 30.5 68 63.6 203 37.0 
χ2 =40.277, df=1, p<0.001 Male 307 69.5 39 36.4 346 63.0 
 
  mean (sd) median  (min-max) mean (sd) 
Median 
 (min-max) 
Mean 
 (sd) 
Median 
 (min-max) Comparison 
Age (yrs) 44.3 (9.8) 45 (20 - 69) 45.5 (9.7) 46 (22 - 71) 44.6 (9.8) 45 (20 - 71) t=1.144, df=545, p=0.253 
Duration of 
substance use 
(years) 
20.1 (11.1) 20 (0 - 47) 19.9 (10.3) 20 (0 - 50) 20 (10.9) 20 (0 - 50) t=-0.212, df=543, p=0.833 
PSQI score 9.8 (4.2) 9 (1 - 18)  
SURE score 48.1 (9.7) 47 (26 - 63) 
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Table 2: Reliability: internal consistency indices by sample and test-retest agreement 
Statement 
IP sample (N=442) OL sample (N=107) Test retest (N=42) 
Corrected 
Item-Total 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Corrected 
Item-Total 
Correlation 
Cronbach's 
Alpha if  
Item Deleted 
Cohen’s κ (95% CI) % of  agreement 
Wanted to sleep better 0.45 0.88 0.61 0.84 0.4 ( 0.0, 0.7 ) 78.6 
Worried about my sleeping 0.48 0.88 0.52 0.84 0.6 ( 0.4, 0.9 ) 81.0 
Woken up tired most 
mornings 0.49 0.88 0.54 0.84 0.8 ( 0.6, 1.0 ) 92.9 
Disturbed by noise 0.31 0.88 0.26 0.85 0.6 ( 0.3, 0.8 ) 78.6 
Disturbed by light 0.31 0.88 0.23 0.85 0.5 ( 0.2, 0.9 ) 85.7 
Felt too unsafe to sleep 0.36 0.88 0.41 0.84 0.4 ( 0.0, 0.9 ) 90.5 
Difficulty falling asleep 0.55 0.88 0.44 0.84 0.9 ( 0.7, 1.0 ) 92.9 
Uncontrollable/ racing 
thoughts when I tried to sleep 0.56 0.88 0.54 0.84 0.8 ( 0.6, 1.0 ) 90.5 
Negative emotions when I 
tried to sleep 0.57 0.88 0.53 0.84 0.8 ( 0.6, 1.0 ) 88.1 
Sleeping tablets or medicines 
to help me sleep 0.35 0.88 0.14 0.85 0.8 ( 0.6, 1.0 ) 90.5 
Drunk alcohol to help me 
sleep 0.41 0.88 0.40 0.84 0.8 ( 0.6, 1.0 ) 95.2 
Street drugs to help me sleep 0.40 0.88 0.16 0.85 0.7 ( 0.4, 1.0 ) 90.5 
Waking up lots in the night 0.43 0.88 0.39 0.84 0.8 ( 0.6, 1.0 ) 90.5 
Woken up in the night and 
drunk caffeinated and/ or 
sugary drinks 
0.21 0.88 0.17 0.85 0.7 ( 0.4, 0.9 ) 88.1 
Woken up in the night and 
drunk alcohol 0.37 0.88 0.30 0.85 0.9 ( 0.7, 1.0 ) 97.6 
Woken up in the night and 
used street drugs 0.41 0.88 0.31 0.85 0.5 ( 0.0, 0.9 ) 90.5 
Woken up in the night and 
smoked tobacco 0.40 0.88 0.37 0.84 1.0 ( 0.9, 1.0 ) 97.6 
Panic attacks in the night 0.46 0.88 0.29 0.85 0.6 ( 0.3, 0.9 ) 88.1 
Vomited in my sleep 0.26 0.88 -  -  1  100 
Dreams which disturbed 
sleep 0.42 0.88 0.35 0.84 0.6 ( 0.3, 0.8 ) 81.0 
Aches and pains that stopped 
me from sleeping 0.45 0.88 0.44 0.84 0.6 ( 0.4, 0.9 ) 81.0 
Felt restless in my sleep 0.53 0.88 0.49 0.84 0.7 ( 0.4, 0.9 ) 83.3 
Woken up feeling confused 
or disoriented 0.49 0.88 0.34 0.85 0.7 ( 0.4, 0.9 ) 85.7 
Woken up with a hangover or 
drunk 0.41 0.88 0.39 0.84 0.7 ( 0.4, 1.0 ) 95.2 
Woken up withdrawing 0.42 0.88 0.43 0.84 0.7 ( 0.4, 1.0 ) 90.5 
Needed alcohol or drugs to 
get out of bed 0.46 0.88 0.31 0.85 0.4 ( 0.0, 0.8 ) 88.1 
Woken up short of breath 0.46 0.88 0.24 0.85 0.5 ( 0.2, 0.9 ) 85.7 
Too tired to think clearly or 
to do things during the day 0.58 0.88 0.53 0.84 0.5 ( 0.2, 0.7 ) 73.8 
Needed caffeine and/ or 
sugary foods or drink to get 
through the day 
0.31 0.88 0.29 0.85 0.7 ( 0.5, 0.9 ) 85.7 
Needed to sleep or to nap 
during the day 0.35 0.88 0.32 0.85 0.8 ( 0.5, 1.0 ) 88.1 
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Table 3: Goodness of fit indices – EFA-Sample IP-a (N=221) 
	  
# of 
factors Rel χ
2 RMSEA CFI TLI 
One 2.1 0.071 0.89 0.88 
Two 1.4 0.042 0.96 0.96 
Three 1.2 0.032 0.98 0.98 
Four 1.1 0.026 0.99 0.99 
Five 1.1 0.015 >0.99 >0.99 
Six 1.1 0.013 >0.99 >0.99 
Seven 1.1 0.004 >0.99 >0.99 
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Table 1: EFA and CFA loadings per sample – final model. 
 
Sample 
IP-a 
(EFA)  
IP-b 
(CFA)  
OL 
(CFA) 
item description MBSP SRSP  MBSP SRSP  MBSP SRSP 
I06 Uncontrollable/ racing thoughts when I tried to sleep 0.9 0.0  1.0    1.0   
I07 Negative emotions when I tried to sleep 0.9 -0.1  1.1    1.0   
I02 Worried about my sleeping 0.8 -0.1  0.9    0.9   
I01 Wanted to sleep better 0.9 -0.1  0.9    1.1   
I05 Difficulty falling asleep 0.8 0.0  0.9    0.9   
I14 Panic attacks in the night 0.6 0.1  0.8    0.7   
I03 Woken up tired most mornings 0.7 0.1  0.8    1.0   
I10 Waking up lots in the night 0.6 0.0  0.7    0.8   
I19 Woken up feeling confused or disoriented 0.7 0.1  0.8    0.7   
I18 Felt restless in my sleep 0.7 0.2  0.8    0.9   
I04 Felt too unsafe to sleep 0.6 0.0  0.7    1.0   
I23 Too tired to think clearly or to do things during the day 0.6 0.3  0.8    1.0   
I16 Dreams which disturbed sleep 0.7 0.0  0.7    0.6   
I17 Aches and pains that stopped me from sleeping 0.6 0.1  0.7    0.8   
I12 Woken up in the night and used street drugs 0.0 0.9    1.0    1.0 
I09 Street drugs to help me sleep -0.1 0.9    1.0    0.7 
I11 Woken up in the night and drunk alcohol -0.1 0.9    0.8    0.8 
I08 Drunk alcohol to help me sleep 0.1 0.7    0.9    1.0 
I20 Woken up with a hangover or drunk 0.2 0.6    0.9    1.1 
I22 Needed alcohol or drugs to get out of bed 0.1 0.7    0.9    1.0 
I15 Vomited in my sleep* 0.2 0.6    0.6    - 
I13 Woken up in the night and smoked tobacco 0.2 0.5    0.6    0.7 
I21 Woken up withdrawing 0.2 0.6    0.7    1.1 
All loadings marked with bold were significant. EFA loadings according to OBLIMIN rotation. 
• In the OL sample, item I15 “vomited in my sleep” was omitted because there were no positive responses. 
  
	   39 
 
Table 5: IRT parameters (p<0.05 in all cases)  
 
  
 Item Discrimination  Difficulty 
MBSP I01 1.98 -1.10 
I02 1.82 -0.33 
I03 1.80 -0.87 
I04 1.51 1.36 
I05 2.14 -0.44 
I06 2.89 -0.35 
I07 2.74 -0.36 
I14 1.70 0.91 
I10 1.39 -0.59 
I16 1.22 -0.59 
I17 1.28 -0.05 
I18 1.80 -0.31 
I19 1.42 0.50 
I23 1.71 -0.15 
SRSP I08 1.87 0.63 
I09 2.09 0.80 
I11 2.27 1.14 
I12 2.38 1.05 
I13 1.32 -0.16 
I15 2.00 2.20 
I20 1.75 0.99 
I21 1.63 0.74 
I22 2.63 0.99 
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Table 6: Pearson correlation coefficients for the final 23-item sleep PROM  
  
MBSP scores SRSP scores Total score 
r p N r p N r p N 
Age -0.1 0.001 547 -0.1 0.005 547 -0.2 <0.001 547 
PSQI score 0.7 <0.001 100 0.3 0.001 100 0.7 <0.001 100 
SURE score -0.5 <0.001 100 -0.6 <0.001 100 -0.6 <0.001 100 
Actigraphy: Sleep Efficiency -0.4 0.044 22 -0.3 0.197 22 -0.5 0.022 22 
Actigraphy: Sleep Latency 0.2 0.283 22 0.2 0.263 22 0.3 0.145 22 
Actigraphy: Total Sleep Time -0.4 0.039 22 -0.1 0.569 22 -0.4 0.062 22 
Actigraphy: Wake Bouts 0.1 0.768 22 0.0 0.913 22 0.0 0.874 22 
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Table 7: Score differences in relation to demographic and clinical characteristics for the final 
23-item sleep PROM 
 
  
Factor 
MBSP SRSP SP 
95% CI Comparison 95% CI Comparison 95% CI Comparison 
Gender  
(Male-Female) ( -0.7 , 0.6 ) t=-0.1, df-547, p=0.922 ( 0.5 , 1.3 ) W=42915.5, p<0.001 ( 0 , 1.8 ) t=1.9, df-547, p=0.057 
Ethnicity  
(White-Other) ( -0.9 , 0.8 ) t=0, df-547, p=0.962 ( -0.9 , 0.1 ) W=19861, p=0.086 ( -1.6 , 0.8 ) t=-0.7, df-547, p=0.492 
Education beyond 16 
years (N-Y) ( -0.2 , 1.1 ) t=1.4, df-545, p=0.148 ( 0.8 , 1.6 ) W=46800, p<0.001 ( 0.8 , 2.6 ) t=3.7, df-545, p<0.001 
Substance use in the 
last 6 months (Y-N) ( 3.5 , 1.9 ) t=6.8, df-544, p<0.001 ( 2.8 , 1.9 ) W=7583, p=p<0.001 ( 6.1 , 4 ) t=9.5, df-544, p<0.001 
Homeless in last 
month (Y-N) ( 0.7 , 2.6 ) t=3.5, df-547, p<0.001 ( 0.8 , 1.9 ) W=23805.5, p<0.001 ( 1.7 , 4.3 ) t=4.7, df-547, p<0.001 
Had paid work in last 
month (Y-N) ( -1.9 , -0.2 ) t=-2.4, df-547, p=0.017 ( -1.5 , -0.4 ) W=16065, p<0.001 ( -3.2 , -0.8 ) t=-3.3, df-547, p=0.001 
Has a diagnosed 
physical health 
problem (Y-N) 
( -0.4 , 2.7 ) t=1.5, df-98, p=0.133 ( -1 , 0.9 ) W=1204, p=0.816 ( -1 , 3.1 ) t=1.1, df-98, p=0.293 
Has a diagnosed 
mental health 
problem (Y-N) 
( 1.4 , 4.3 ) t=4, df-98, p<0.001 ( -0.5 , 1.5 ) W=1343, p=0.235 ( 1.4 , 5.4 ) t=3.3, df-98, p=0.001 
Ever diagnosed 
insomnia (Y/N) ( 1.8 , 3.4 ) t=6.4, df-522, p<0.001 ( -0.1 , 0.9 ) W=24339, p=0.066 ( 1.9 , 4.1 ) t=5.4, df-522, p<0.001 
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Table 8: Substance Use Sleep Scale (SUSS)* 
 
 
Mind and Body Sleep Problems - thinking about the last week 
 
 
No 
 
Yes 
1. I have worried about my sleeping □ □ 
2. I have wanted to sleep better □ □ 
3. I have had difficulty falling asleep □ □ 
4. I have felt too unsafe to sleep □ □ 
5. I have had uncontrollable/ racing thoughts when I tried to sleep □ □ 
6. I have had negative emotions (such as anger, guilt or anxiety) when I tried to sleep □ □ 
7. I have had aches and pains that stopped me from sleeping □ □ 
8. I have been waking up lots in the night □ □ 
9. I have had panic attacks in the night □ □ 
10. I have had dreams which have disturbed my sleep □ □ 
11. I have felt restless in my sleep (e.g. jumpy, twitchy or itchy legs) □ □ 
12. I have woken up feeling confused or disoriented □ □ 
13. I have woken up tired most mornings □ □ 
14. I have been too tired to think clearly or to do things during the day □ □ 
 
Substance Related Sleep Problems – thinking about the last week 
 
 
No 
 
Yes 
15. I have drunk alcohol to help me sleep □ □ 
16. I have taken street drugs to help me sleep □ □ 
17. I have woken up in the night and drunk alcohol □ □ 
18. I have woken up in the night and used street drugs □ □ 
19. I have woken up in the night and smoked tobacco □ □ 
20. I have vomited in my sleep □ □ 
21. I have woken up with a hangover or drunk □ □ 
22. I have woken up withdrawing □ □ 
23. I have needed alcohol or drugs to get out of bed □ □ 
 
* Items score 0 (No) or 1 (Yes), so total scores range from 0-23 (where lower scores denote better 
sleep and higher scores denote worse sleep)	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